This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Olaussen KA et al. (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355: 983–991
Potti A et al. (2006) A genomic strategy to refine prognosis in early stage non-small cell lung cancer. N Engl J Med 355: 570–580
Chen HY et al. (2007) A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 356: 11–20
Bepler G et al. (2006) RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small cell lung cancer. J Clin Oncol 24: 4731–4737
Rosell R et al. (2005) ERCC1 mRNA-based randomized phase III trial of docetaxel (doc) doublets with cisplatin (cis) or gemcitabine (gem) in stage IV non-small-cell lung cancer (NSCLC) patients (p) [abstract #7002]. J Clin Oncol 23 (Suppl 16S part I)
Acknowledgements
The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Heist, R., Liu, G. & Zhou, W. Should oncologists measure the mRNA and protein expression levels of ERCC1 and RRM1 in non-small-cell lung cancer?. Nat Rev Clin Oncol 4, 564–565 (2007). https://doi.org/10.1038/ncponc0909
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncponc0909